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With the rise of Next-Generation-Sequencing (NGS) methods, Micro-RNAs (miRNAs)
have achieved an important position in the research landscape and have been found
to present valuable diagnostic tools in various diseases such as multiple sclerosis or
lung cancer. There is also emerging evidence that miRNAs play an important role
in the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease (AD)
or Parkinson’s disease (PD). Apparently, these diseases come along with changes in
miRNA expression patterns which led to attempts from researchers to use these small
RNA species from several body fluids for a better diagnosis and in order to observe
disease progression. Additionally, it became evident that microbial commensals might
play an important role for pathology development and were shown to have a significantly
different composition in patients suffering from neurodegeneration compared with
healthy controls. As it could recently be shown that secreted miRNAs are able to
enter microbial organisms, it is conceivable that the host’s miRNA might affect the
gut microbial ecosystem. As such, miRNAs may inherit a central role in shaping
the “diseased microbiome” and thereby mutually act on the characteristics of these
neurodegenerative diseases. We have therefore (1) compiled a list of miRNAs known
to be associated with AD and/or PD, (2) performed an in silico target screen for
binding sites of these miRNA on human gut metagenome sequences and (3) evaluated
the hit list for interesting matches potentially relevant to the etiology of AD and or
PD. The examination of protein identifiers connected to bacterial secretion system,
lipopolysaccharide biosynthesis and biofilm formation revealed an overlap of 37 bacterial
proteins that were targeted by human miRNAs. The identified links of miRNAs to the
biological processes of bacteria connected to AD and PD have yet to be validated
via in vivo experiments. However, our results show a promising new approach for
understanding aspects of these neurodegenerative diseases in light of the regulation
of the microbiome.
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INTRODUCTION
Micro RNAs (miRNAs) are an important subclass of small
regulatory RNA. They are present in virtually all kingdoms
of life and involved in crucial metabolic functions. Their
main function is the downregulation of a target transcript via
complementary base pairing. In general, these transcriptional
modifiers are located within the synthesizing cell but are also
able to translocate via gap junctional cell-cell contacts or
exosomal release (Lemcke et al., 2015; Zong et al., 2016). They
influence a variety of cellular processes such as autophagy,
differentiation and stress-response (Zhu et al., 2009; Leung and
Sharp, 2010; Mendell and Olson, 2012; Vidigal and Ventura,
2015; Gozuacik et al., 2017). Moreover, miRNAs have been
found to contribute to pathological conditions, for example
cancer development or autoimmunity (Xiao and Rajewsky, 2009).
In the case of neurodegenerative diseases such as Parkinson’s
disease (PD) or Alzheimer’s disease (AD), miRNA patterns of
patients differ from healthy control groups. Recent examples
for differential miRNA abundances are selective upregulations
of let-7b and let-7e in cerebrospinal fluid (CSF) within AD
patients (Derkow et al., 2018), or miR-24 and miR-205 that
distinguished PD patients from controls in a comparably small
cohort (Marques et al., 2017).
Many characteristics are shared between AD and PD, such as
pathological mechanisms (e.g., protein aggregation) or genetic
variants. Therefore, it has been postulated that these diseases
may share similar alterations that could trigger comparable
pathological pathways. Using literature mining of GWAS studies,
regulatory networks enriched with AD- and PD-associated genes
could be identified (Ramanan and Saykin, 2013; Sys et al.,
2018). Nowadays miRNAs can be extracted from nearly every
kind of body fluid or type of tissue (Weber et al., 2010),
providing easy access to this information. Interestingly, it was
already demonstrated in 2009 that miRNAs from feces might
serve as biomarkers for colon cancer and active ulcerative
colitis (Ahmed et al., 2009). This has been confirmed by many
subsequent studies (Link et al., 2010; Kuo, 2013; Ren et al., 2015;
Yau et al., 2016).
miRNAs within feces usually originate from exfoliated cells
of the host’s gastrointestinal tract, but also possibly from food
(Koga et al., 2010). Evidence for this was acquired by feeding
mice with RNA obtained from Brassica oleracea. Exogenous
plant miRNA was detectable within the animal’s serum, feces
and tissues for up to 72 h (Liang et al., 2014). Interestingly,
not only epithelial cells in the walls of the gut lumen are
affected by the excreted or ingested miRNAs, but also the
host’s microbiome. Liu and colleagues reported in 2016 that
host miRNA can enter bacterial cells and regulate growth
behavior and certain bacterial gene transcripts (Qin and Wade,
2018). In their study, Fusobacterium nucleatum cultured with
human miR-515-5p showed an increased ratio of 16S rRNA/23S
rRNA transcripts.
A different approach showed that it is possible to change the
microbiome through miRNAs in vivo. Du et al. (2018) infected
miR-146a-deficient mice with Listeria monocytogenes. This led
to a differently developed gut microbiome and an increased
infection tolerance against Listeria monocytogenes compared to
wild type mice.
With respect to neurodegenerative diseases, the connection
between host and gut microbiome has shifted increasingly
into the focus of research (Scheperjans et al., 2015;
Brandscheid et al., 2017; Cattaneo et al., 2017; Vogt
et al., 2017; Bäuerl et al., 2018; Brenner et al., 2018;
Gerhardt and Mohajeri, 2018). The contribution of altered
miRNA patterns toward these changes and their possible
impact on pathology is still an open question. Until
now, miRNA analyses of feces collected from patients
suffering from neurodegenerative diseases are rather
scarce. However, consistent changes of miRNAs (miR-
16, miR-21, mir-34a and miR-222) have been detected in
both plasma and feces derived from the same individual
(Tarallo et al., 2014).
This encouraged us to conduct the following two-step analysis.
The first step was the collection of common miRNA patterns
within blood and tissue from AD and PD patients, based on the
data from seven studies. The second step consisted in identifying
potential bacterial target sites for the selected miRNAs.
MATERIALS AND METHODS
Differentially Expressed-miRNAs
Lists of differentially expressed miRNAs in AD and PD were
aggregated from seven different studies (see Supplementary
Table S1, Martins et al., 2011; Soreq et al., 2013; Burgos et al.,
2014; Gui et al., 2015; Love et al., 2015; Lugli et al., 2015; Ding
et al., 2016; Santoro et al., 2018). The lists were filtered after a
p-value cut-off of 5%; the respective micro-RNAs were split in
AD, PD up- and downregulated. The resulting lists were used as
an input for the target scan analysis.
Target Scan Analysis
Target Scan analysis for potential targets of the micro-RNAs
on the human gut metagenome was performed with miRanda
(v3.3a; Enright et al., 2003). Parameters for target filtering
were: -strict -go -2 -ge -8 -sc 150.00 -en -25.00 -scale
3.00. For the target scan, the gut metagenome database was
created based on the work by Qin et al. (2010). However,
we only used species with a complete annotation available
via the NCBI RefSeq (O’Leary et al., 2016). Afterwards, the
miRanda hits were grouped by micro-RNA family affiliation
as well as by organism and aggregated on family level.
Afterwards, the miRanda output was parsed using a custom
bash script. We intersected the miRanda output with the
annotation file for each respective species and kept all
protein IDs that were targeted (Supplementary Table S5).
The protein IDs for the hits were used for the subsequent
target analysis.
GO-Terms for Human miRNA Targets on
Bacterial Genes
GO terms were retrieved via GORetriever (McCarthy et al.,
2006). The dataset was reduced using the GOSlimViewer with the
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metagenomic GOSlim set. Enrichment was done with Blast2GO
(Gotz et al., 2008).
RESULTS
miRNAs Differentially Expressed in AD
and PD
In the first step of our meta-analysis, 346 miRNAs were
aggregated from 7 studies evaluating miRNAs in AD and PD (see
Supplementary Tables S1, S8). The miRNAs were grouped into
different categories, according to their up- or downregulation
FIGURE 1 | Venn-Diagram of miRNAs being differentially expressed in
patients suffering from AD and PD versus healthy controls. The overlaps
summarize miRNAs being detected in both conditions.
TABLE 1 | Commonly upregulated miRNAs in AD and PD.
Identifier Pathway
Analysis Results
AD reference PD reference
hsa-miR-30c-2-3p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-592 Burgos et al., 2014 Burgos et al., 2014
hsa-miR-148a-3p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-30a-5p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-190a-5p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-769-3p Burgos et al., 2014 Tatura et al., 2016
hsa-mir-378c∗ Biofilm formation
(P. aeruginosa),
Bacterial Secretion
Pathway, Quorum
Sensing
Burgos et al., 2014 Soreq et al., 2013
hsa-mir-485-5p Gui et al., 2015 Gui et al., 2015
∗miRNAs that are involved in one of the analyzed pathways (see Results: Pathway
analysis).
and their role in AD or PD. We were particularly interested in
miRNAs being differentially expressed in both diseases. Figure 1
summarizes the number of miRNAs being up- or downregulated
in both, AD and PD patients, compared to healthy controls (p-
value < 0.5). Out of 95 miRNAs upregulated in AD patients,
8 miRNAs were upregulated in patients with PD as well (see
TABLE 2 | Commonly downregulated miRNAs in AD and PD.
Identifier Pathway
Analysis
Results
AD reference PD reference
hsa-miR-124-3p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-127-3p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-128-1-5p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-128-3p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-1299∗ Biofilm formation
(V. cholerae)
Burgos et al., 2014 Burgos et al., 2014
hsa-miR-132-3p Burgos et al., 2014 Burgos et al., 2014
hsa-mir-132-5p∗, ∗∗ Biofilm formation
(E. coli), Bacterial
Secretion
Pathway,
Quorum Sensing
Burgos et al., 2014;
Gui et al., 2015
Burgos et al., 2014;
Gui et al., 2015
hsa-miR-134-5p Burgos et al., 2014 Burgos et al., 2014
hsa-mir-136-3p Burgos et al., 2014;
Gui et al., 2015
Burgos et al., 2014;
Gui et al., 2015
hsa-miR-136-5p∗ Biofilm formation
(E. coli), Quorum
Sensing
Burgos et al., 2014 Burgos et al., 2014
hsa-miR-138-1-3p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-138-5p∗ Biofilm formation
(E. coli), Quorum
Sensing
Burgos et al., 2014 Burgos et al., 2014
hsa-miR-139-3p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-139-5p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-150-5p Lugli et al., 2015 Burgos et al., 2014
hsa-mir-151 Gui et al., 2015 Gui et al., 2015
hsa-mir-16-2 Gui et al., 2015 Gui et al., 2015
hsa-miR-212-3p Burgos et al., 2014 Burgos et al., 2014
hsa-mir-29c∗∗ Gui et al., 2015 Gui et al., 2015
hsa-miR-323a-3p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-323b-3p Burgos et al., 2014 Burgos et al., 2014
hsa-mir-331-5p Gui et al., 2015 Gui et al., 2015
hsa-miR-370-3p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-376a-5p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-377-5p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-383-5p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-409-3p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-431-3p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-433-3p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-485-5p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-539-5p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-744-3p Burgos et al., 2014 Burgos et al., 2014
hsa-miR-760 Burgos et al., 2014 Burgos et al., 2014
∗miRNAs that are involved in one of the analyzed pathways (see Results: Pathway
analysis); ∗∗miRNAs that have been chosen for selective analysis (see Results:
Selection of miRNAs).
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also Table 1). The total number of upregulated miRNAs in PD
compared to controls is 82. The comparison of downregulated
miRNAs in both, AD patients (134 miRNAs) and PD patients (84
miRNAs), reveals a number of 35 expressed miRNAs (see also
Table 2). Interestingly, 5 miRNAs found to be upregulated in AD
were significantly downregulated in PD. Vice versa, 4 miRNAs
that were found to be downregulated in AD were upregulated in
PD. All candidates are listed in the Supplementary Table S2.
Crosstalk Between miRNA and
Microbiome Composition
To investigate a potential crosstalk between bacteria and host
miRNAs, as illustrated in Figure 2, we aimed to detect potential
target sites of miRNAs within bacterial genomes. All 346 miRNAs
were screened against 207 bacterial reference genomes, taken
from a database of human gut metagenomic samples (listed in
Supplementary Tables S3, S4). The most prevalent bacterial
phyla in the database were Firmicutes, Proteobacteria and
Bacteroidetes. The target scan using miRanda (v3.3a; Enright
et al., 2003) revealed 20363 potential binding sites on the
205 bacterial reference genomes for 327 unique miRNAs. It
is worth mentioning that each miRNA has the potential to
target multiple locations and vice versa; a particular region
can be associated to multiple miRNAs. Interestingly, eleven
out of the selected miRNAs were connected to over 200
protein identifiers. Here, the miRNA hsa-miR-1226-5p had
the maximum amount of potential target sites with 1109 hits
predicted by miRanda, followed by hsa-miR-1183 with 780,
hsa-miR-4767 with 683 and hsa-miR-3916 with 604 possible
binding sites.
The bar plot in Figure 3A shows the number of different
species per phylum of the reference database. The largest phylum
with the highest number of different species is Firmicutes,
followed by Proteobacteria and Bacteroidetes. The correlation
between total miRNA hits, as predicted by miRanda, and
the length of the reference genomes per taxonomy identifier
is shown in Figure 3B. As expected, the number of hits
grows with genome length. The outlier on the top right
is Streptomyces sparsogenes. Figure 3C shows the miRNA
match per phylum for the complete set of miRNAs. Similar
to the reference database, Firmicutes, Proteobacteria and
Bacteroidetes were the most prominent taxa. In Figure 3D
the number of unique proteins targeted in the respective
phyla are given. It is evident here that Firmicutes and
Proteobacteria have the most hits. Compared to the hits
of unique miRNAs, the ratio of unique proteins that were
targeted between Firmicutes and Proteobacteria is shifted toward
the latter. Moreover, Synergistetes were targeted at a much
higher frequency. Upon closer examination, the counts for
protein identifiers in Actinobacteria were mostly composed
of Streptomyces sparsogenes targeted by hsa-miR-4767. This
combination accounted for 203 of 683 hits.
Investigation of Potential Targets by
Screening KEGG Pathways
Because several bacterial biofilm components (like functional
amyloids or bacterial endotoxins) are linked to the aggravation
of symptoms in AD and PD, we screened a number
of reference pathways from the Kyoto Encyclopedia of
Genes and Genomes (KEGG) Orthology (KO) Database
for proteins that were targeted by the constructed
miRNA set (Ogata et al., 1999; Kanehisa and Goto, 2000;
Kanehisa et al., 2016, 2017). Pathways of particular interest
were the bacterial secretion system, lipopolysaccharide
biosynthesis and the biofilm formation pathway of three
different species.
It is worth mentioning that only protein IDs mapped to a KO
pathway could be considered in the analysis.
Furthermore, several species were mapped to different
pathways simultaneously.
FIGURE 2 | Hypothesized crosstalk between the host miRNAs being released into the gut lumen and the gut microbiome.
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FIGURE 3 | General results of the target scan. (A) The species composition of our genomic reference database. (B) The number of miRNA hits plotted against the
reference genome length of the different phyla. (C) The number of miRNAs that revealed hits with a bacterial organism is shown per phylum, and (D) the number of
unique protein IDs, which were predicted to have putative target sites for miRNAs, in different phyla. The colors refer to different phyla. The legend for all graphs is
given beneath the lower plots.
Bacterial Secretion System
The bacterial secretion system is mainly responsible for shuttling
proteins across cell membranes. Furthermore, bacterial secretion
is linked to virulence and interaction with the host’s immune
system. Especially in the case of AD, latent infection is
increasingly recognized as a potential cause for the disease (Green
and Mecsas, 2016; Fülöp et al., 2018).
Figure 4 shows an overview of the bacterial secretion system
from KEGG. Among the successfully mapped identifiers,
mostly Type II secretion pathway proteins were targeted.
Those belong primarily to the Sec-SRP class, that is shown
in Figure 4. The targeted identifiers (gspE, secA, secF, secG,
secY, SRP54, ftsY, tatA, virB8, virD4, yidC) revealed an overlap
with the genomic positions of 20 original protein IDs for 16
miRNAs on 19 taxonomic units (Supplementary Table S5).
miRNA hsa-miR-3180-5p targeted three different proteins (secA,
secF and gspE) in three different species (Ruminococcus
champanellensis 18P13 = JCM 17042, Pseudomonas sp.
ADP, Klebsiella sp. 4_1_44FAA). hsa-miR-132-5p and
hsa-miR-1183 targeted two protein IDs in two different
species, respectively.
Lipopolysaccharide Biosynthesis
Bacterial lipopolysaccharides (LPS) are known to trigger
a widespread host immune system response as well as
neuroinflammation (Poltorak et al., 1998; Li et al., 2016).
Increased LPS levels were found in both, the bloodstream
and the brain of AD patients (Zhao et al., 2017; Zhan
et al., 2018). Assessment of pathway members of the bacterial
lipopolysaccharide biosynthesis pathway that harbor putative
miRNA binding sites led to six hits, namely: lpxA, lpxL,
waaC, kdsC, gmhB, gmhD. In Figure 5, the lipopolysaccharide
biosynthesis is shown with protein hits colored in pink.
From the list of targeting miRNAs, those six proteins had 7 hits
on 6 taxonomic entries, belonging to the Bacteroidetes and the
Proteobacteria. Among all hits, only hsa-miR-3180-5p targeted
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the same protein in two different Klebsiella species, namely lpxL
(Supplementary Table S5).
Biofilm Formation
Functional amyloids, such as curli, are often components of
bacterial biofilms (Sawyer et al., 2012) which have the potential to
change the virulence and invasiveness of bacteria. Furthermore,
it has been shown that biofilm components were able to increase
amyloidogenesis, even when only fed to rats (Chen et al., 2016).
We examined this pathway class via KEGG pathway mapping for
the organism Escherichia coli (see Table 3 and Figure 6) as well as
for Vibrio cholerae (Supplementary Figure S1) and Pseudomonas
aeruginosa (Supplementary Figure S2).
Interestingly, CsgD, a master regulator of biofilm formation
and the synthesis of curli fimbriae (Brombacher et al., 2006),
was targeted on Klebsiella sp. 4_1_44FAA. Since this is a
multispecies protein for Enterobacteriaceae, it also maps in
the E. coli pathway map. Other proteins targeted are PYG,
GlgA and GlgC, as shown in Figure 6. All these proteins are
involved in the glycogen biosynthesis. For the Vibrio cholerae
pathway map (Supplementary Figure S1), seven proteins
offered target sites for miRNAs in the target scan. WecC is
involved in the biosynthesis of polysaccharides. RpoN seems
to be involved in bacterial virulence (Kazmierczak et al.,
2005). Fis is involved in flagellar movement and controls
virulence-associated genes (Jakovleva et al., 2012). GspE is a
protein involved in the general secretion pathway. PaaK is
associated with phenylactetat-CoA ligase, an enzyme involved
in energy metabolism. WecB seems to be involved in capsule
precursor proteins (Swartley et al., 1998). miRNA targets within
Pseudomonas aeruginosa were ImpH and Hcp (for pathway
overview see Supplementary Figure S2). ImpH is involved in
transport through membranes, while Hcp seems to be involved
in the interaction of E. coli with human endothelial cells
(Zhou et al., 2012).
Target Scan Results for a Subset of
miRNAs
To investigate the impact of individual miRNAs on potential
bacterial targets, we shortlisted six miRNAs based on systematic
literature research, as well as those two miRNAs who had the
highest amount of hits, according to the target scan.
mir-132, a well-known mediator of neurodegenerative
diseases (Hernandez-Rapp et al., 2017; El Fatimy et al., 2018),
targeted 32 different species in 4 different phyla. Figure 7 shows
the miRNA hits on annotated proteins per phylum. It becomes
evident that, compared to the other phyla, Bacteroidetes are
more frequently targeted, despite the fact that they are only the
third largest phylum in the overall taxonomic composition of
the database. Conversely, Firmicutes, representing the largest
taxonomic group in the database were targeted at a much
lower frequency.
The scan for the mir-29 family revealed that they all mostly
target Firmicutes, Proteobacteria and Bacteroidetes at the same
ratio. Mir-29b, with 162 species in 6 phyla, had the highest
number of predicted target sites. miR-125b had most hits on
the phylum Proteobacteria, followed by Bacteroidetes. Mir-
146, a miRNA associated with the immune system response
FIGURE 4 | Bacterial Secretion System from KEGG. Proteins encoded by bacterial genome regions that revealed miRNA target matches are colored in pink.
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FIGURE 5 | Lipopolysaccharide Biosynthesis from KEGG. Proteins encoded by bacterial genome regions that revealed miRNA target matches are colored in pink.
TABLE 3 | List of mapping proteins in biofilm formation of Vibrio cholerae,
Escherichia coli, and Pseudomonas aeruginosa.
Vibrio cholerae Escherichia coli Pseudomonas aeruginosa
CysE PYG ImpH
WecB GlgA Hcp
PaaK GlgC
GspE CsgD
WecC RcsB
RpoN
Fis
and upregulation in AD (Arroyo et al., 2018), targeted mainly
Firmicutes and Bacteroidetes, with only one hit on Proteobacteria
and Actinobacteria, respectively.
A recent study by Du et al. (2018) showed that overexpression
of miR-146a is linked to an altered gut microbiome in mice.
Supplementary Table S7 lists the exact hits for any protein
and any species that could potentially be targeted by hsa-
miR-146a-5p. With this in mind, we investigated the taxa
that were downregulated upon mir-146a upregulation. Out
of the 45 Proteobacteria present in our database, hsa-miR-
146a-5p targeted exactly 1 species, Desulfovibrio sp. A2,
on one protein, the chromosomal replication inhibitor
protein DnaA. Within the seven Prevotellaceae, Prevotella
salivae DSM was targeted on the diguanylate cyclase.
Parasutella was not targeted at all, since this species was
not contained in our gut database. According to Du et al.
(2018), overabundant taxa were Alistipes, Blautia, Coprococcus
and Ruminococcus. For this list of taxa, no targets were
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FIGURE 6 | Biofilm Formation Pathway using KEGG pathway mapping for E. coli. Proteins encoded by bacterial genome regions that revealed miRNA target
matches are colored in pink.
predicted for hsa-miR-146a-5p. In conclusion, we found two
potential hits on taxa that were downregulated and none
on taxa that were upregulated in Du et al. (2018) given our
genomic database.
Figure 8 highlights two very interesting miRNAs, namely
hsa-miR-1226 and hsa-miR-4767, which were selected due
to their high number of potential target sites reported
by miRanda (see section “Crosstalk Between miRNA and
Microbiome Composition”).
hsa-miR-1226 was predicted to have in total 1109 matches
whereas hsa-miR-4767 had 683 hits. Interestingly, the latter
had an unexpected high amount of 203 hits on Streptomyces
sparsogenes, accounting for almost one third of the total amount
of hits. In both cases, highly targeted phyla were Firmicutes as
well as Proteobacteria. Supplementary Table S6 lists the GO-
terms for the selected miRNAs.
Finally, we were interested in putative targets hits on serine
proteases. Bacterial HTRA serine proteases have been implicated
to play a role in the cleavage of the amyloid precursor protein.
Their inhibition causes β-amyloid to accumulate in a culture
of astrocyte cells (Grau et al., 2005). A first examination
revealed two hits on serine proteases in Lactobacillus antri
and Flavonifractor plautii by hsa-miR-664a-5p and hsa-miR-
1248, respectively.
DISCUSSION
The search for a cure for neurodegenerative diseases related
to protein misfolding such as AD and PD has also led to
studies of the gut microbiome and its potential dysregulation.
Different studies have demonstrated a connection between the
etiology of AD or PD and microbiome alterations (Cattaneo
et al., 2017; Vogt et al., 2017). However, the question still
remains if and how exactly the host communicates with its
internal gut microbiota. A novel and interesting link between
host and bacteria was demonstrated by Liu et al. (2016), who
showed that miRNAs from the host might be able to enter
bacterial cells and downregulate the expression of bacterial
target sequences (Liu et al., 2016). Additionally, sequences as
short as miRNAs and acting like miRNAs have been naturally
found in bacteria (Nejman-Falen´czyk et al., 2015), giving further
evidence that small RNAs of this size might be active in
bacteria. We therefore hypothesized the existence of a crosstalk
between microRNAs commonly associated with AD or PD in
humans and target sites on bacterial genomes within the human
gut metagenome.
Another potential fit for this size requirement are
external guide sequences that mediate cleavage by RNAse P
(Davies-Sala et al., 2015). These sequences consist of about 13 to
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FIGURE 7 | Number of hits from specific miRNAs per phylum. The bar plots show the number of hits from miRNAs (A) hsa-miR-132, (B) hsa-miR-125b,
(C) hsa-miR-146a, (D) hsa-miR-29a, (E) hsa-miR-29b and (F) hsa-miR-29c counted for different phyla. The legend can be found at the bottom. The colors refer to
different phyla.
19 nucleotides complementary to their target site and possess
a 3’RCCA nucleotide signature necessary for the cleavage.
The only miRNA showing hits and meeting these criteria
was hsa-miR-770-5p.
We screened a broad initial dataset of over 300 miRNAs in
order to gain a detailed overview over potential interactions
between miRNAs and the gut metagenome. The first target
scan on gut bacterial genomes for miRNAs involved in
AD and PD revealed hits for almost all of the microRNAs
investigated in this study, resulting in a plethora of
potential interactions.
The sheer volume of interactions predicted by miRanda
made it necessary to further reduce the set of targets. This was
accomplished by focusing on all hits on bacterial pathways that
were assumed relevant in AD and/or PD as well as a core set
of miRNAs prominently highlighted in previous studies for their
involvement in the microbiome in AD/PD.
The initial results of the target screen made evident that
some miRNAs target multiple proteins. This went as far as 1109
predicted hits on protein IDs for hsa-miR-1226-5p. While some
of these hits may certainly be false positives, miR-1226-5p was
among the miRNAs investigated in Liu et al. (2016), where it
upregulated the growth of E. coli. In the same vein, the miRNAs
hsa-miR-1183, hsa-miR-4767, hsa-miR-3916, hsa-miR-3180-5p,
hsa-miR-1248, hsa-miR-1301-3p, hsa-miR-378c, hsa-miR-1538,
hsa-miR-671-5p and hsa-miR-939-5p show promise for future
investigations. Each one had over 200 hits of protein identifiers.
These could either be spurious hits on repetitive sequences,
devoid of any functional meaning, or hits on conserved protein
stretches, enabling a single miRNA to target a functional class of
proteins over a broad array of species. For eukaryotes it is known
that particular miRNA can target several proteins connected in
one pathway and that some miRNA families are highly conserved
(Kehl et al., 2017).
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FIGURE 8 | Number of hits per phylum from miRNAs with the largest target matching. In (A), the hit counts of hsa-miR-1226 per phylum are given, in (B) the
number of targeted regions of hsa-miR-4767 counted for different phyla. The legend can be found at the bottom. The colors refer to different phyla.
Since we performed only an in silico scan for miRNA hits
on bacterial reference genomes, any detected target requires
validation. At the present time, the necessary circumstances that
have to be met for a human miRNA to be effective in bacteria
are unclear. Properties like target seed site conservation are well
known features in eukaryotic miRNAs. If and how this feature
might be present in miRNA hits on bacterial sequences, remains
to be seen (Ellwanger et al., 2011).
Moreover, data regarding fecal miRNA are lacking for AD
and PD compared to data for blood and other biofluids and
tissues. While it is possible to separate the miRNAs into groups
of up- or down-regulated, this might be misleading for several
reasons. Due to the lack of data, we did not investigate a single
study containing fecal miRNA in AD or PD. Therefore, we do
not know if the composition differs between body sites. Even
within the same body fluids, different studies showed discordant
results. Since it is unclear how miRNAs are exactly imported into
and processed within bacteria, selective import might change the
ratios of the relevant miRNAs.
As the next step, bacterial pathways and protein cascades
with a known involvement in AD or PD were searched. It
needs to be mentioned at this point that we only considered the
identifiers that could be mapped to KEGG Pathways, as well as
some manual exceptions. This includes the lipopolysaccharide
biosynthesis. Lipopolysaccharides (LPS) of E. coli are known to
be elevated in the brain of patients with AD. Furthermore, it
has been hypothesized that gut derived LPS are able to traverse
the intestinal barrier and travel to the brain. LPS derived from
gram negative bacteria colocalises with plaques. Additionally,
LPS levels are elevated in the bloodstream of AD patients. This
pattern fits well with other studies attesting a link between
neuroinflammation and AD (Zhao et al., 2017; Zhan et al., 2018).
In PD, abnormal levels of an LPS-binding protein were found to
be a biomarker for both gastrointestinal inflammation and PD
(Pal et al., 2015).
The next pathway we evaluated was biofilm formation. Biofilm
formation leads to a multitude of functional adaptations for
the bacteria. Bacteria are able to secrete numerous functional
amyloids, among them Curli, Fap, HpaG and FUBA. With respect
to the etiology of AD and PD, it is known that bacterial amyloids
are able to propagate amyloid formation in vivo. This is supported
by rodent studies, where rats that were fed with bacterial
amyloids showed enhanced alpha synuclein formation in the
brain. This leads to the speculation that biofilm components
from the gut microbiota are able to cross-seed to the brain,
where they induce amyloidogenesis (Lundmark et al., 2005;
Chen et al., 2016; Del Tredici and Braak, 2016). More indirect
links between biofilm formation and pathogenesis are connected
to increased cell adhesion, increased virulence contributing to
“leaky gut” and a general weakening of endothelial barriers,
observed as well in AD as in PD (Sawyer et al., 2012;
Friedland and Chapman, 2017).
Secretion across lipid membranes is linked to virulence and
host immune evasion (Green and Mecsas, 2016). Especially with
respect to AD, there is a paradigm shift toward latent chronic
infection as a main cause for the disease (Fülöp et al., 2018).
Coincidentally, one of the first validated functions for a micro-
RNA-sized RNA in bacteria was regulating the virulence of said
bacteria (Nejman-Falen´czyk et al., 2015).
Microbiome dysbiosis in general has been previously
recognized in both, AD and PD, and there are several studies,
that found different abundances of bacteria between cases and
controls through the analysis of fecal 16S rRNA (Vogt et al.,
2017; Qian et al., 2018; Zhuang et al., 2018). Some of the species
mentioned here were regrettably not present in our genomic
database, but, for example, Ruminococcaceae had target site
predictions on all of their 12 members in our collection of
bacterial genomes. That differential expression of a miRNA,
in principle, can alter bacterial abundance has been shown by
Du et al. (2018), who knocked out miR-146 in mice. If the
miRNA-microbiome crosstalk should prove true, it would be
definitively worth to investigate further whether the targeting
miRNAs have an influence on the species composition of the
microbiome by regulating bacterial transcription.
For future studies an in vivo validation of putative hits is
necessary. Furthermore, since most known bacterial small RNAs
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are >50–200 nucleotides (Choi et al., 2017), considering longer
transcripts might provide further insights. In addition, other
classes of small RNAs such as tRNA fragments, which are known
to be associated to regulatory pathways in other species, could
be considered.
Conclusively, our in silico target screen found several miRNAs
that may represent key regulators in bacterial pathways relevant
to AD or PD. If the human miRNAs should prove to be
effective in regulating bacterial transcription, this could lead
to several new insights regarding both the microbiome host
interaction and the treatment of neurodegenerative diseases. As
such, the microbiome-miRNA crosstalk might contribute to the
idea of what constitutes a “healthy microbiome,” beyond the mere
abundance of bacterial taxa toward differential regulations of
global pathways. Moreover, there are currently several miRNAs
undergoing clinical studies for their use as therapeutics for
example against cancer or hepatitis (Rupaimoole and Slack,
2017). Thus, the miRNAs might be used as a therapy option to
revert the microbiome to a desired state. This may even be applied
years before the disease breaks out, so as to keep the pathological
changes beyond a threshold level in order to prevent the outbreak
of the disease altogether.
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